Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial
Zampieri et al., Journal of Critical Care, doi:10.1016/j.jcrc.2024.154892
https://c19early.org/zampieri.html